Lincomycin

Mechanism :

The mode of action of lincomycin is the inhibition of protein synthesis by the inhibition of the binding of aminoacyl sRNA to the messenger ribosome complex at the 50S ribosomal unit.

Indication :

Serious infections due to sensitive gram-positive organisms (staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when the patient is intolerant of, or the organism resistant to other appropriate antibiotics.

Contraindications :

Hypersensitivity to the drug or patients who have previously been found hypersensitive to clindamycin, and in the newborn.

Dosing :

<1 month:

Safety and efficacy not established.

>1 month:

10 to 20 mg/kg/day intravenously in 2-3 divided doses OR 10 mg/kg IM 1-2 times a day depending on the severity of the infection may be infused in divided doses.

Adverse Effect :

Leukopenia, agranulocytosis, neutropenia, thrombocytopenic purpura, hypotension, hypersensitivity reactions (serum sickness, angioneurotic edema, anaphylaxis), vomiting, abdominal distress, nausea, persistent diarrhea, abnormal liver function tests, pruritus, vaginitis, urticaria, skin rashes, exfoliative and vesiculobullous dermatitis.

Local Reactions: Local irritation, induration, pain, and sterile abscess formation have been seen with IM injection.

Interaction :

Neuromuscular Blocking Agents: Lincomycin may enhance the action of other neuromuscular blocking agents. Therefore, it should be used in caution in patients receiving such agents.
Erythromycin: Antagonism between lincomycin and erythromycin has been demonstrated. Because of possible clinical significance, the two drugs should not be administered concurrently.

Hepatic Dose :

No dose adjustments are recommended. Use with caution in patients with hepatic impairment.